Previous Close | 30.71 |
1-Year Change | 113.26% |
6-Months Change | 39.09% |
3-Months Change | 3.71% |
Moving Avg (50d) | 31.438 |
Moving Avg (200d) | 24.323 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.65B |
Beta (3-Years) | 2.29 |
Revenue Growth (ttm) | 3676.56% |
Net Profit Margin (ttm) | -13.65% |
Return On Assets (ttm) | -7.82% |
EPS (ttm) | -0.27 |
PE Ratio (ttm) | -113.74 |
Dividend Yield | % |
Asset Description: | TG Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2025-02-11 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
31.324 | 32.245 | 32.86 | 33.781 | 35.316 | 36.852 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |